According to the results of this study and the latest international classification of ROP in 2021,64 PEDF protein therapy alone or in combination with anti‐VEGF could keep ROP below stage 3 by suppressing pathological neovascularization and reducing the avascular area as well as artery tortuosity. Here, VEGFA is linked to retinopathy of prematurity.